Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.47 |
| ▸ | GRN | P28799 | 2/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4688182 | 0.81 | ALDH1A1 (0.45) | KMT2APOLBALDH1A1MEN1BCL2 | |
| SCHEMBL27746881 | 0.81 | CYP19A1 (0.44) | CYP19A1GRNSORT1KMT2APOLB | |
| SCHEMBL1482977 | 0.81 | KMT2A (0.46) | CYP19A1GRNSORT1KMT2APOLB | |
| SCHEMBL5216996 | 0.74 | HSP90AA1 (0.48) | KMT2AALDH1A1TSHRPTGDR2NR1H2 | |
| SCHEMBL4692553 | 0.73 | MARS1 (0.62) | GRNSORT1KMT2AMDM2 | |
| SCHEMBL1484330 | 0.73 | AGTR1 (0.46) | KMT2APOLBALDH1A1MEN1 | |
| SCHEMBL1484332 | 0.73 | AGTR1 (0.46) | KMT2APOLBALDH1A1MEN1 | |
| SCHEMBL12829728 | 0.73 | AGTR1 (0.46) | KMT2APOLBALDH1A1MEN1 | |
| SCHEMBL12755620 | 0.73 | AGTR1 (0.46) | KMT2APOLBALDH1A1MEN1 | |
| SCHEMBL4689814 | 0.72 | GRN (0.64) | GRNSORT1KMT2APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | PPARD, PPARA, PPARG | CYP19A1 398/4885GRN 4143/4885SORT1 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.